Salem R, Johnson GE, Kim E, et al. - Researchers assessed objective response rate (ORR) as well as duration of response (DoR) among patients with solitary unresectable HCC managed with yttrium-90 glass microspheres, in the LEGACY (Local radioEmbolization using Glass Microspheres for the Assessment of Tumor Control with Y-90) study which is a multicenter, single-arm, retrospective study. Total 162 patients were involved, 60.5% were Eastern Cooperative Oncology Group 0, and the median tumor size was 2.7 cm (range: 1-8) as per blinded, independent, central review. The estimated ORR (best response) was 88.3%, and a DoR ≥ 6 months was shown by 62.2%. A 3-year overall survival of 86.6% was observed for all patients and it was estimated to be 92.8% for those neoadjuvant patients with resected or transplanted liver. Findings revealed that radioembolization conferred clinical meaningful response rates as well as prolonged DoR in the treatment of unresectable, solitary HCC ≤ 8 cm.